Company Overview - Codexis, Inc. is a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics [3] - The company leverages its proprietary CodeEvolver® technology platform to discover, develop, and enhance novel, high-performance enzymes [3] - Codexis is developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route [3] Upcoming Events - Codexis will attend the Cantor Global Healthcare Conference from September 3-5, 2025, in New York, New York [1] - Management will participate in a fireside chat on September 4, 2025, at 3:55 pm ET, with a live webcast available on the company's Investor Relations website [2]

Core Insights - Codexis, Inc. has appointed Cynthia Collins to its Board of Directors, bringing extensive experience in the pharmaceutical and biotech industry [1][2] - The company aims to expand its commercial footprint with its ECO Synthesis toolbox, which is positioned to unlock the potential of RNA-based therapeutics [2] Company Overview - Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, utilizing its proprietary CodeEvolver® technology platform [3] - The company is developing the ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route [3] - Codexis' unique enzymes are designed to improve yields, reduce energy usage and waste generation, and enhance efficiency in manufacturing [3] Leadership Background - Cynthia Collins has over four decades of experience in the pharmaceutical and biotech sectors, currently serving as Executive Chair and interim CEO of Nutcracker Therapeutics [2] - Her previous roles include CEO of Editas Medicine, where she oversaw the first clinical trial of an in vivo CRISPR gene editing therapy, and various leadership positions at GE Healthcare and Baxter Healthcare [2]